For asbestos-exposed individuals, the specter of mesothelioma is always lurking in the background. Every cough or discomfort raises alarm bells that it could be the first sign of a deadly diagnosis. Researchers have been exploring the utility of a screening breath test to help allay these fears and provide an early detection tool. They reported on their
Dr. Giuseppe Giaccone ranks among the world’s most highly respected practitioners in the treatment and study of lung cancer and in developmental therapeutics. He is a medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital and serves as Chief of Thoracic Oncology and Associate Director for Clinical Research at the Sandra and Edward Meyer Cancer
Back in 2009, the International Association for the Study of Lung Cancer presented a model they’d developed to help stage malignant mesothelioma cases. Since then, additional data has been added to the model’s database to continue enhancing its accuracy. This week, the group’s members attending its annual conference in Singapore learned that the model is
Dr. Stephen Liu’s clinical practice focuses on thoracic malignancies, including lung cancer, thymic malignancies, and pleural cancers including malignant pleural mesothelioma. He has significant expertise in the development of novel therapeutic agents and in combining treatment protocols with the goal of improving patient outcomes. Dr. Liu’s philosophy of care is in alignment with the mission
Dr. Frank Detterbeck is board-certified in general surgery as well as in thoracic and cardiac surgery. As Chief of Thoracic Surgery at Yale Cancer Center, he has earned a national reputation for performing minimally invasive surgeries for the treatment of lung cancer, malignant mesothelioma, and other thoracic malignancies and life-threatening diseases. In addition to valuing
Dr. Roy Herbst is a nationally recognized clinician-scientist who has dedicated himself to thoracic cancer treatment and research. He is a leader in the treatment of lung cancer and is renowned for his work in developmental therapeutics and personalized therapies that link the individual patient’s genetic profile to the treatment offered. His primary focus is
Identifying the right treatment plan is one of the many challenges faced by mesothelioma patients and their physicians. Those whose tumors are operable need to decide whether to pursue an aggressive form of surgery that removes the affected lung or to go with a less invasive procedure. A report issued today suggests that those who
Dr. John D. Mitchell is the Chief of General Thoracic Surgery within the Division of Cardiothoracic Surgery at the University of Colorado and the CU Cancer Center. He has extensive experience in treating cancers of the lungs, including malignant pleural mesothelioma, and focuses his research on lung cancer, surgical treatment of lung infection, and lung
Dr. Camidge is a thoracic oncologist at the University of Colorado. He has been the Director of CU’s Thoracic Oncology Clinical Program and Clinical Research Program since 2007. His approach to treating malignant pleural mesothelioma and lung cancer focuses on a personalized approach in which treatment plans are based on the results of specific tests
Because asbestos has been used all over the world, malignant pleural mesothelioma has become a global problem. The search for effective treatments is being conducted all over the world, and researchers from the Hyogo College of Medicine recently shared positive results from a study of an inhalable gene therapy.